Democratizing Biomanufacturing of Recombinant Proteins & Subunit Vaccines

Dr. Kerry R. Love
CEO, Sunflower Therapeutics PBC
Presented at DCVMN Annual Meeting

September 21, 2023

Contact: kerry@sunflowertx.com
Sunflower is an early-stage company delivering next-generation biomanufacturing solutions to global innovators servicing a >$500B market for protein medicines, vaccines and food.

Just like anyone can grow sunflowers anywhere, our solutions are easy to use and empower anyone to efficiently make proteins anywhere.
Our Goal: Make Protein Manufacturing More Accessible

Accessibility = Easy to obtain + Easy to use

- Lower cost
- Small footprint
- Deployable in simple facilities

- Simple
- Automated
- Efficient
- Flexible (multi-product)
- Scalable
Sunflower Manufacturing Systems: Automated Hardware to Enable Capacity Anywhere

DAISY Petal™
Discovery/R&D Continuous Fermentation (up to grams per week)
Taking orders now!

DAHLIA Petal™
Translational Development Continuous Fermentation (up to 100s of grams per week)
Early access launch in 2024

DAHLIA™ System
Efficient Commercial Production Protein Bulk Production (up to 10 kg annually in <50m²)
Early access launch in 2025

SUNFLOWER’S INTUITIVE APPROACH FACILITATES PROCESS TRANSFERS & SCALING

Presented at DCVMN Meeting - September 21 2023
NOT FOR DISTRIBUTION
One Investment for a Flexible Formulary

PLATFORMABLE PROCESSES
using integrated and continuous techniques

NEXT-GENERATION EQUIPMENT
single-use consumables for rapid process transitions

MULTI-PRODUCT FLEXIBLE CAPACITY
for business agility and sustainability